Altimmune’s pemvidutide shows promising Phase IIb MASH results; see key benefits, risks, and a bullish outlook. Read here for ...

Epstein sees a clear direction of travel in private markets. “The trend line is toward standardized data and repeatable ...

The plain, though somewhat striking, reality is that Advanced Micro Devices’ ($AMD) share price has more than doubled this ...

NVIDIA, Micron Technology and Thermo Fisher lead today's top analyst picks, each showing strong growth trends and strategic ...

When New York City’s congestion pricing plan launched on January 5, 2025, the sky did not fall—but traffic did. After months ...

Zacks spotlights NVIDIA, Micron and Thermo Fisher in its latest Analyst Blog, highlighting AI-driven tailwinds, memory-market ...

Leidos shows Q3 beats, strong growth, a $69B backlog, rising guidance and continued returns with solid demand and valuation ...

Gold eased in European trade on Friday, giving back the late-week spike and slipping into a corrective slide toward the mid-$4,100s as the macro backdrop pivoted from “urgent haven” to “measured ...

ObesityWeek 2025, held in Atlanta from November 4-7, showcased unprecedented clinical data that signals a fundamental shift in the obesity treatment landscape. The most striking breakthrough at ...

The private company that promised to be “financially viable on its own” is losing money — and using government subsidies to ...

I find this interview that Steve Eisman did with Evercore ISI's Glenn Schorr to be illuminating. The Private Credit Panic. The most personally illuminating thing was the ROE difference between a trad ...

Produced Higher Margins, Lower Operating Expenses, and Significantly Narrowed Losses Compared to Q2 2025New Product Introductions and Sales ...